Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy)
article
OA: closed
CC0
⤵ 31 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This pilot study investigated the efficacy of a "draw-back" therapy for endometriosis, involving a decreasing dosage of nafarelin, a gonadotropin-releasing hormone agonist.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (27)
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- Dosage aspects of danazol therapy in endometriosis. via openalex
- Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness via openalex
- Effect of Treatment with GnRH Agonists on New Markers of Bone Metabolism via openalex
- Excretion of urinary n-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- Human uterine endometrium and endometriotic tissue transplanted into nude mice. Morphologic effects of various steroid hormones. via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study via openalex
- Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis via openalex
- Nafarelin in the Treatment of Endometriosis via openalex
- Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain via openalex
- Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. via openalex
- Spontaneous and steroid-induced recurrence of endometriosis after suppression by a gonadotropin-releasing hormone antagonist in the rat via openalex
- The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover via openalex
- The Use of GnRH Agonists in the Medical Therapy of Endometriosis in the Woman with Pain via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. via openalex
- Urinary N-Telopeptides to Monitor Bone Resorption While on GnRH Agonist Therapy via openalex
- W6717624033 via openalex
- W201040832 via openalex
- W1987759607 via openalex
- W2013079995 via openalex
- W2014736171 via openalex
- W2075860102 via openalex
- W2114962190 via openalex
- W2129449855 via openalex
Cited by (31)
- Chrysin-loaded PLGA nanoparticles alleviate the implantation of endometriotic lesions via attenuation of peritoneal inflammation and downregulating NF-κB activation-driven expression of angiogenic factors 2025
- Extended GnRH Agonist and NETA Add-Back: An Effective and Safe Option for Refractory Endometriosis/Adenomyosis Pain 2025
- Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis 2023
- Agonists of gonadotropin-releasing-hormone and add-back-therapy 2023
- Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? 2023
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- GnRH Agonists and Antagonists in Endometriosis and Adenomyosis Therapy 2022
- Place et modalités du traitement médical de l’endométriose 2022
- Endometriosis 2021
- Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis 2020
- Use of Dienogest or Gonadotropin Releasing Hormone Agonist with Add back Hormone Therapy in Longterm Endometriosis Medical Management 2018
- Curative effect of 1.88‐mg and 3.75‐mg gonadotrophin‐releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study 2017
- Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use 2017
- Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy 2017
- Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis 2012
- Hormonal strategy for the primary or secondary treatment of endometriosis 2012
- Endometriosis 2012
- [Endometriosis: necessary and sequential therapeutic procedures and guidelines]. 2011
- Endometriosis: Necessary and Sequential Therapeutic Procedures and Guidelines 2010
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Clinical Aspects of Endometriosis 2010
- Medical Management of Endometriosis 2008
- Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix 2008
- GnRH-Analoga und Add-back-Verfahren 2008
- Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide GnRH Antagonist Elagolix 2008
- Noninvasive assessment of ectopic uterine tissue development in rats using magnetic resonance imaging 2007
- Endometriosis 2007
- Emerging drugs in endometriosis 2006
- GnRH-antagonists in reproductive medicine 2005
- Gonadotropin Releasing Honnone Agonist and Antagonist for Endometriosis 2003
- Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density 2003
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:13:41.710148+00:00
- unpaywall
- last seen: 2026-06-04T02:00:05.705006+00:00
License: CC0
· commercial use OK